CLOs on the Move


 
Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cidara.com
  • 6310 Nancy Ridge Drive Suite 101
    San Diego, CA USA 92121
  • Phone: 858.752.6170

Executives

Name Title Contact Details
Jessica Oien
General Counsel and Secretary Profile
Jessica Oien
General Counsel and Secretary Profile

Similar Companies

Agrivida

Agrivida is developing and commercializing solutions that are the next evolutionary step in animal nutrition, using the plant as a factory to produce and deliver highly differentiated products. We are transforming the economics of enzyme and animal feed production through our use of plant-expressed enzymes and plant modification to develop transformational products for monogastric and ruminant animal nutrition.

Pharmexa-Epimmune

Pharmexa-Epimmune Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Celtic Pharma (Main) US

Celtic Pharma (Main) US is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Children's Hospital Oakland Research Institute

Children's Hospital Oakland Research Institute is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.